Market Spotlight: Uterine Cancer
Market Spotlight: Uterine Cancer
$1,318.00
This Market Spotlight report covers the uterine cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the uterine cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 385,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 404,300 incident cases by 2028.
- In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by 2028.
- Merck & Co’s Keytruda and Eisai’s Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes, respectively.
- The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with only one drug in the NDA/BLA stage.
- Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the uterine cancer space comprise topline Phase III trial results and an estimated PDUFA date for dostarlimab.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 43.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.4 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 95% of trials in Phase I–II, and only 5% in Phase III–IV.
- The US has a substantial lead in the number of uterine neoplasms clinical trials globally, while Spain leads the major European markets.
- Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.
- AstraZeneca and Sanofi lead the industry sponsors with the highest overall number of clinical trials for uterine neoplasms.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Chemotherapy
10 Hormone therapy
10 Palliative care
11 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
22 RECENT EVENTS AND ANALYST OPINION
22 Bavencio for Uterine Cancer (May 30, 2020)
23 Trodelvy for Uterine Cancer (May 13, 2020)
25 DKN-01 for Uterine Cancer (April 23, 2020)
27 Retifanlimab for Uterine Cancer (July 2, 2019)
28 Trodelvy for Uterine Cancer (April 29, 2019)
29 TAK-117 for Uterine Cancer (March 20, 2019)
30 Dostarlimab for Uterine Cancer (March 19, 2019)
31 DKN-01 for Uterine Cancer (March 18, 2019)
33 KEY UPCOMING EVENTS
34 KEY REGULATORY EVENTS
34 Dostarlimab Submitted For (Relatively) Broad Endometrial Cancer Indication
34 FDA Issues Pair Of RTOR Approvals To Keytruda/Lenvima Combo, Erleada
35 PROBABILITY OF SUCCESS
36 LICENSING AND ASSET ACQUISITION DEALS
36 Tyligand Gets Onapristone ER Rights From Context
36 Deals Shaping The Medical Industry, August 2019
37 REVENUE OPPORTUNITY
38 CLINICAL TRIAL LANDSCAPE
39 Sponsors by status
40 Sponsors by phase
42 BIBLIOGRAPHY
42 Prescription information
43 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of uterine cancer, 2019–28
17 Figure 2: Overview of pipeline drugs for uterine cancer in the US
17 Figure 3: Pipeline drugs for uterine cancer, by company
18 Figure 4: Pipeline drugs for uterine cancer, by drug type
18 Figure 5: Pipeline drugs for uterine cancer, by classification
23 Figure 6: Bavencio for Uterine Cancer (May 30, 2020): Phase II – TROPHIMMUN (Gestational Trophoblastic Neoplasias (GTN))
25 Figure 7: Trodelvy for Uterine Cancer (May 13, 2020): Phase I/II – Epithelial Cancer
27 Figure 8: DKN-01 for Uterine Cancer (April 23, 2020): Phase II – Gynecologic Malignancies (P204)
31 Figure 9: Dostarlimab for Uterine Cancer (March 19, 2019): Phase I/II – GARNET
32 Figure 10: DKN-01 for Uterine Cancer (March 18, 2019): Phase II – Gynecologic Malignancies (P204)
33 Figure 11: Key upcoming events in uterine cancer
35 Figure 12: Probability of success in the uterine cancer pipeline
38 Figure 13: Clinical trials in uterine cancer
38 Figure 14: Top 10 drugs for clinical trials in uterine cancer
39 Figure 15: Top 10 companies for clinical trials in uterine cancer
39 Figure 16: Trial locations in uterine cancer
40 Figure 17: Uterine cancer trials status
41 Figure 18: Uterine cancer trials sponsors by phase
LIST OF TABLES
12 Table 1: Incident cases of uterine cancer, 2019–28
14 Table 2: Five-year prevalent cases of uterine cancer, 2019–28
16 Table 3: Marketed drugs for uterine cancer
19 Table 4: Pipeline drugs for uterine cancer in the US
22 Table 5: Bavencio for Uterine Cancer (May 30, 2020)
24 Table 6: Trodelvy for Uterine Cancer (May 13, 2020)
26 Table 7: DKN-01 for Uterine Cancer (April 23, 2020)
27 Table 8: Retifanlimab for Uterine Cancer (July 2, 2019)
28 Table 9: Trodelvy for Uterine Cancer (April 29, 2019)
29 Table 10: TAK-117 for Uterine Cancer (March 20, 2019)
30 Table 11: Dostarlimab for Uterine Cancer (March 19, 2019)
31 Table 12: DKN-01 for Uterine Cancer (March 18, 2019)
37 Table 13: Historical global sales, by drug ($m), 2015–19
37 Table 14: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Gastrointestinal Stromal Tumor (GIST) 
Sign up to the